Now Playing
Opinion|Videos|March 31, 2025
The Role of ctDNA in CRC
Author(s)John L. Marshall, MD, Mark Lewis, MD
Panelists discuss how circulating tumor DNA (ctDNA) serves as a promising biomarker for early detection, treatment monitoring, and recurrence surveillance in patients with colorectal cancer (CRC).
Advertisement
Episodes in this series
Advertisement
Related to this article
Bruce Haffty, MD, and Mutlay Sayan, MD, on building radiation oncology at Rutgers, the future of the field, and a remarkable journey from eastern Turkey to Harvard faculty.
Marcio A. Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with intensity-modulated proton therapy.
The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.
Community physicians must be “smart” when it comes to initiating outpatient care with agents like ramantamig for multiple myeloma, according to Jeffrey V. Matous, MD.
In the phase 3 Alliance A071801 trial, postoperative fractionated SRS improved surgical bed control vs single-fraction SRS without added toxicity.
In the phase 3 evERA trial, interim overall survival data showed a positive trend in favor of giredestrant/everolimus vs endocrine therapy plus everolimus.
William A. Hall, MD, reviews resection rates, surgical complications, and SBRT target volumes from the SOFT Preop study in pancreatic cancer.
Andy Liao, MD, discusses the distribution of KRAS mutations in biliary tract cancer and the different classes of KRAS inhibitors in development.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Pirtobrutinib in Frontline CLL/SLL
2
Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer
3
Assessing IMPT Outcomes Across Localized Prostate Cancer Risk Groups
4
FDA Discussion Prompts Voluntary Withdrawal of BLA for I-DXd in ES-SCLC
5